Biophytis Signs Master Service Agreement with Intsel Chimos
(24/7 MARKET NEWS) – Biophytis SA (NASDAQ:BPTS) reported, this morning, that it signed a master service agreement with Intsel Chimos, in which that pharmaceutical company will become Biophytis’s Pharmaceutical Operator/Exploitant in France for Sarconeos (BIO101) in the context of the early access program application, requested for the treatment of severe forms of COVID-19, if approved.
Biophytis is at $0.6201, up $0.1951 (+45.91%), on 2 million premarket shares.
Its 52-week trading range is $0.3501 to $3.36. It’s cleared most of its February resistance levels and may try to challenge its February 2nd trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to 247marketnews.com or https://247marketnews.com/terms-disclaimer/ for further information.